Unknown

Dataset Information

0

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.


ABSTRACT: The adoptive transfer of T cells expressing anti-CD19 chimeric antigen receptors (CARs) has shown remarkable curative potential against advanced B-cell malignancies, but multiple trials have also reported patient relapses due to the emergence of CD19-negative leukemic cells. Here, we report the design and optimization of single-chain, bispecific CARs that trigger robust cytotoxicity against target cells expressing either CD19 or CD20, two clinically validated targets for B-cell malignancies. We determined the structural parameters required for efficient dual-antigen recognition, and we demonstrate that optimized bispecific CARs can control both wild-type B-cell lymphoma and CD19(-) mutants with equal efficiency in vivo To our knowledge, this is the first bispecific CAR capable of preventing antigen escape by performing true OR-gate signal computation on a clinically relevant pair of tumor-associated antigens. The CD19-OR-CD20 CAR is fully compatible with existing T-cell manufacturing procedures and implementable by current clinical protocols. These results present an effective solution to the challenge of antigen escape in CD19 CAR T-cell therapy, and they highlight the utility of structure-based rational design in the development of receptors with higher-level complexity. Cancer Immunol Res; 4(6); 498-508. ©2016 AACR

SUBMITTER: Zah E 

PROVIDER: S-EPMC4933590 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.

Zah Eugenia E   Lin Meng-Yin MY   Silva-Benedict Anne A   Jensen Michael C MC   Chen Yvonne Y YY  

Cancer immunology research 20160408 6


The adoptive transfer of T cells expressing anti-CD19 chimeric antigen receptors (CARs) has shown remarkable curative potential against advanced B-cell malignancies, but multiple trials have also reported patient relapses due to the emergence of CD19-negative leukemic cells. Here, we report the design and optimization of single-chain, bispecific CARs that trigger robust cytotoxicity against target cells expressing either CD19 or CD20, two clinically validated targets for B-cell malignancies. We  ...[more]

Similar Datasets

| S-EPMC3589159 | biostudies-literature
| S-EPMC8948246 | biostudies-literature
| S-EPMC6322669 | biostudies-literature
| S-EPMC4623422 | biostudies-literature
| S-EPMC10275707 | biostudies-literature
| S-EPMC10935961 | biostudies-literature
| S-EPMC4891234 | biostudies-literature
| S-EPMC7062259 | biostudies-literature
| S-EPMC3669363 | biostudies-literature
| S-EPMC3383803 | biostudies-literature